Calcium polycarbophil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Calcium polycarbophil
Accession Number
DB14684
Description

Calcium polycarbophil is a stool stabilizer. Based on its chemical structure, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol presenting a calcium atom as a counter-ion. Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.

Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.

Type
Small Molecule
Groups
Approved
Synonyms
  • Calcium polycarbophil
  • Polycarbophil calcium
  • Polycarbophil, calcium

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Polycarbophil is used to treat constipation and to help maintain regular bowel movements.

Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.

Mechanism of action

It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.

Absorption

Calcium polycarbophil is not absorbed from the intestine.

Volume of distribution

Calcium polycarbophil is not absorbed from the intestine.

Protein binding

Calcium polycarbophil is not absorbed from the intestine.

Metabolism

Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.

Route of elimination

Excreted in feces.

Half-life

Calcium polycarbophil is not absorbed from the intestine.

Clearance

Calcium polycarbophil is not absorbed from the intestine.

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium polycarbophil.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Calcium polycarbophil.
AcetyldigitoxinCalcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
AclidiniumThe therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Aclidinium.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium polycarbophil.
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Alfacalcidol.
AlfentanilThe therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Alloin.
AmantadineThe therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Calcium polycarbophil.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
  • Take with a full glass of water.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Active Moieties
NameKindUNIICASInChI Key
CalciumsaltSY7Q814VUP7440-70-2OYPRJOBELJOOCE-UHFFFAOYSA-N
PolycarbophilsaltW25LM17A4W9003-97-8Not applicable
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Best ChoiceTablet, film coated625 mg/1OralBest Choice (Valu Merchandisers Company)2019-04-16Not applicableUS flag
Calcium PolycarbophilTablet, film coated625 mg/1OralCardinal Health2020-11-18Not applicableUS flag
Calcium Polycarbophil 625 mgTablet625 mg/1OralREMEDYREPACK INC.2018-10-052020-05-27US flag
Calcium Polycarbophil 625 mgTablet625 mg/1OralREMEDYREPACK INC.2016-10-102018-09-05US flag
Calcium Polycarbophil 625 mgTablet625 mg/1OralReliable 1 Laboratories LLC2015-11-01Not applicableUS flag
Care One FiberTablet, film coated625 mg/1OralAmerican Sales Company2004-03-302013-02-22US flag
Equalactin - Tab 625mgTabletOralNumark Laboratories, Inc.1996-12-312009-07-31Canada flag
Equalactin LaxativeTablet625 mg/1OralNumark Brands, Inc1986-11-21Not applicableUS flag
Equate fiber therapyTablet, film coated625 mg/1OralWalmart Stores1996-11-052015-11-19US flag
FiberTablet, film coated625 mg/1OralWestern Family Foods1998-01-192016-12-08US flag

Categories

ATC Codes
A06AC08 — Polycarbophil calcium
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
8F049NKY49
CAS number
126040-58-2

References

General References
  1. Danhof IE: Pharmacology, toxicology, clinical efficacy, and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy. 1982 Jan-Feb;2(1):18-28. [PubMed:6765389]
  2. Monograph [Link]
  3. webmd [Link]
Wikipedia
Polycarbophil_calcium
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentHER2 Negative Breast Cancer / HER2-Negative Breast Cancer / Leptomeningeal Carcinomatosis / Leptomeningeal Metastases / Tumors Metastatic to Brain1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral500 mg/1
Tablet, film coatedOral625 mg/1
TabletOral625 mg/1
CapsuleOral625 mg/1
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on September 06, 2018 02:00 / Updated on April 17, 2021 10:37